Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KATE3
2020-002818-41Phase 3Completed
- Sponsor
- Roche
- Start
- Dec 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing trastuzumab emtansine + atezolizumab with trastuzumab emtansine + placebo (2 arms). Primary endpoint: Progression-free survival. Started Dec 2020; status: completed.
02
Drugs
trastuzumab emtansineatezolizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2020-002818-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002818-41.